Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Income from Continuing Operations data on file, last reported at 49965473.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 69.8% year-over-year to 49965473.0 in Q1 2026; TTM through Mar 2026 was 241082926.0, a 179.3% decrease from a year earlier, with the FY2025 full-year figure at 161231000.0, down 119.71% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 49965473.0, up from 84151718.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for FULC reached as high as 40216583.0 in Q2 2024 and fell as low as 192456000.0 in Q4 2022.
• Historically, Income from Continuing Operations has averaged 52127032.76 across 5 years, with a median of 41971239.0 in 2025.
• Across the five-year window, Income from Continuing Operations sank 310.77% in 2022 and soared 231.2% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 192456000.0 in 2022, then surged by 77.6% to 43106074.0 in 2023, then tumbled by 65.71% to 71431000.0 in 2024, then declined by 17.81% to 84151718.0 in 2025, then jumped by 40.62% to 49965473.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 49965473.0 in Q1 2026, 84151718.0 in Q4 2025, and 64994496.0 in Q3 2025.